GlassScriptPhysician profile
Megan L Johnson
NPI 1063864783
$4,725.06
in general payments reported to CMS, 2019-2025
30 companies · $1,217 in 2025
The $1,217 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $611 · 2022: $882 · 2023: $872 · 2024: $1,143 · 2025: $1,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,232.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $726.25 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $495.41 | 2021-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $453.76 | 2021-2025 | Xifaxan, Trulance, Uceris |
| Regeneron Healthcare Solutions, INC. | $338.25 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $316.78 | 2021-2025 | Tremfya, Stelara, Simponi |
| Madrigal Pharmaceuticals | $313.56 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $270.80 | 2022-2025 | |
| Qol Medical, LLC | $204.21 | 2021-2025 | Sucraid |
| Gilead Sciences, INC. | $193.76 | 2023-2025 | |
| Ardelyx, INC. | $163.42 | 2024-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $160.73 | 2022-2025 | Linzess |
| Boston Scientific Corporation | $137.65 | 2025 | Ams 700 |
| Nuvasive, INC. | $136.90 | 2021 | |
| Intercept Pharmaceuticals, INC. | $114.24 | 2021-2025 | Ocaliva |
| Aimmune Therapeutics, INC. | $90.72 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $84.02 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $71.89 | 2022-2024 | Dificid |
| Celgene Corporation | $64.23 | 2022-2023 | Zeposia |
| Amgen INC. | $60.22 | 2021-2023 | Avsola, Amjevita |
| Ipsen Biopharmaceuticals, INC | $56.19 | 2025 | Iqirvo |
| Lilly USA, LLC | $49.47 | 2024 | Omvoh |
| Urogen Pharma, INC. | $39.34 | 2025 | |
| Ucb, INC. | $36.76 | 2024 | Cimzia |
| Celltrion USA INC. | $35.69 | 2025 | Vegzelma |
| Nestle Healthcare Nutrition INC. | $33.72 | 2022-2023 | |
| Inspire Medical Systems, INC. | $20.12 | 2025 | Inspire |
| Ironshore Pharmaceuticals INC. | $20.09 | 2024 | |
| Pfizer INC. | $14.55 | 2021 | |
| Baxter Healthcare | $12.67 | 2022 | |
| Organon LLC | $9.66 | 2023 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.